Cerebral hemodynamic changes and their effects on cognitive function in patients with Parkinson's disease complicated with orthostatic hypotension Authors: Jinyu Wang, Yaqin Yu, Kaili Zhang, Ruipeng Wang, Junwei Zhang, Donghai Li, Weihong Yan Published: 2026 ABSTRACT ObjectiveThis article explores the relationship between OH and cerebral hemodynamics in PD patients, and clarifies the correlation between OH and cognitive function in PD patients.MethodsThe included PD cases were divided into OH positive and OH negative groups according to Active standing test (AST). In the supine position test, cerebral blood flow velocity (CBFv) and pulsitility index (PI) were continuously monitored by TCD, and blood pressure and heart rate in the supine position and standing position for 1st, 3rd and 5th minute were recorded.ResultsIn the chi-square test, 87.5% of patients with Parkinson's disease with orthostatic hypotension (PD-OH) had poor W spike correction, while only 12.2% of patients in Parkinson's disease with non-orthostatic hypotension (PD-NOH) group had OH symptoms, and 14.6% of patients had poor W spike correction. MoCA scores were significantly lower, and the prevalence of cognitive decline (CD) was significantly higher, in the OH with poor W spike callback group than in the W spike disappearance (WD) and normal response groups (P < 0.01). The results showed that mean cerebral blood flow velocity ratio (mCBFvR, % of baseline) was slightly positively correlated with MoCA score. Univariate regression analysis of disease duration, LEDD and OH were positively associated with CI in PD patients.ConclusionCBFv reduction was positively correlated with CD. This study points out that PD patients have poor W spike callback with OH, and then reduces the cerebral blood perfusion in the prolonged upright state, which may explain the impaired cognitive function in PD patients with OH. OH may serve as a “marker” of the overall burden of the disease, rather than being the sole direct cause of cognitive impairment. Introduction PD is a prevalent neurological disorder affecting middle-aged and elderly individuals. In addition to the characteristic motor symptoms, it can also manifest autonomic dysfunction. OH, a complication seen in 9.6% to 58.0% [1], [2] of PD patients, significantly increases the risk of falls and fractures, thereby reducing overall quality of life. OH is arguably the most debilitating manifestation of autonomic failure. Advancements in hemodynamic profiling through continuous blood pressure monitoring have revealed four principal subtypes: initial OH, delayed blood pressure recovery, classic OH, and delayed OH. [3], [4] The clinical manifestations of OH are typically subtle and frequently overlooked, intertwined with cognitive symptoms. [5] It is a fact that individuals impacted by this condition often experience confusion of consciousness, which exhibit a substantial correlation with syncope, accidental falls, and increased mortality rates among elderly patients. A meta-analysis of 913 prospective studies involving 121 individuals indicated that OH was associated with a 1.5-fold increase in all-cause mortality over a 5-year period [6], [7], underscoring the necessity for further research into OH. Current research indicates that PD may be linked to cardiovascular autonomic dysfunction [8], [9], representing a component of the same neurodegenerative pathway. The relevant influencing factors of PD combined with OH have been studied both at home and abroad. It reported that, in comparison to patients with the tremor phenotype, PD patients with PIGD are more susceptible to OH [10]. In summary, it is currently considered that risk factors for OH in PD patients exhibit characteristics such as high LEDD, a high total UPDRS score, and constipation, alongside a notably high UPDRS-III score. OH damages the perfusion of the organs above the heart (most notably the brain), causing symptoms of insufficient tissue perfusion. The mechanisms behind the hemodynamic alterations in PD with OH remain unclear. [11], [12] There is growing evidence of an association between OH and increased risk of dementia in PD patients. [13], [14], [15] OH has been shown to lead to impaired cerebral blood supply. The most accepted hypothesis is that chronic hypoxia secondary to recurrent episodes of cerebral perfusion insufficiency leads to increased vascular lesions and synergistic neurodegeneration [16], leading to cognitive impairment, so further research on OH is necessary. Our study revealed the effect of PD combined with OH on cerebral hemodynamics in patients and confirmed its association with cognitive decline. To better understand these changes, we measured the mean cerebral blood flow velocity (mCBFv) and PI of the unilateral middle cerebral artery (MCA) in both supine and upright positions using TCD, and recorded the changes in the waveform curves. Defects in the autonomic nervous system's regulation of vascular tone, heart rate, and contractility can lead to excessive blood retention in the viscera and lower limb vessels when upright, causing reduced blood flow, decreased cardiac output, and significantly lowered blood pressure, known as upright intolerance. Recumbent test can assess the reactivity of the body after position change to diagnose different types of orthostatic intolerance syndrome. However, the relationship between Orthostatic Cerebral Hypoperfusion (OCHO) [12] and the disappearance of W spike [17], [18] and cognitive decline needs further investigation. In order to clarify the characteristics of OH in PD and the relationship between cerebral artery blood hemodynamics and cognitive dysfunction, this study has positive significance for guiding further treatment plans, early prevention of fall and fracture risk, and improving quality of life. Material and methods Participants Ninety-six primary PD patients were included in the outpatient and inpatient department of Neurology of Shanxi Bethune Hospital from October 2022 to October 2023. (Fig. 1).Fig. 1Flow chart of study population and classification.Patients with Parkinson's disease (PD) were screened and included based on inclusion criteria. All included subjects underwent a supine-to-standing transcranial Doppler (TCD) test. Based on the test result, subjects were classified into PD with orthostatic hypotension (PD-OH, n = 24) or PD without non-orthostatic hypotension (PD-NOH, n = 41). Subsequently, all subjects were evaluated with the Montreal Cognitive Assessment (MoCA); those scoring <26 were classified as PD with cognitive decline (PD-CD, n = 28), and those scoring ≥26 as PD with normal cognition (PD-NC, n = 37). Data were analyzed using SPSS software to obtain final results. Exclusion criteria: poor temporal window penetration (n = 31).PD, Parkinson's disease; TCD, transcranial Doppler; PD-OH, Parkinson's disease with orthostatic hypotension; PD-NOH, Parkinson's disease with non-orthostatic hypotension; MoCA, Montreal Cognitive Assessment; PD-CD, Parkinson's disease with cognitive decline; PD-NC, Parkinson's disease with normal cognition;Fig. 1 Flow chart of study population and classification. Patients with Parkinson's disease (PD) were screened and included based on inclusion criteria. All included subjects underwent a supine-to-standing transcranial Doppler (TCD) test. Based on the test result, subjects were classified into PD with orthostatic hypotension (PD-OH, n = 24) or PD without non-orthostatic hypotension (PD-NOH, n = 41). Subsequently, all subjects were evaluated with the Montreal Cognitive Assessment (MoCA); those scoring <26 were classified as PD with cognitive decline (PD-CD, n = 28), and those scoring ≥26 as PD with normal cognition (PD-NC, n = 37). Data were analyzed using SPSS software to obtain final results. Exclusion criteria: poor temporal window penetration (n = 31). PD, Parkinson's disease; TCD, transcranial Doppler; PD-OH, Parkinson's disease with orthostatic hypotension; PD-NOH, Parkinson's disease with non-orthostatic hypotension; MoCA, Montreal Cognitive Assessment; PD-CD, Parkinson's disease with cognitive decline; PD-NC, Parkinson's disease with normal cognition; Inclusion criteria for PD patients were: (a) Conforms to the “Diagnostic Criteria for Parkinson's Disease in China (2016 Edition)” formulated by the PD and Movement Disorders Group of the Neurology Branch of the Chinese Medical Association in 2016. [19] (b) The onset age is limited to individuals aged over 50 years. The age at enrollment must be ≤75 years. (c) Deep brain stimulation (DBS) was not performed. (d) Be able to complete the scale assessment. (e) All the patients or the family members were informed about the examination items and signed the informed consent form. Exclusion criteria were: (a) Other motor disorders that cause postural gait abnormalities and tremor. (b) Inflammatory, pharmacogenic, pesticide poisoning, vascular, traumatic, neoplastic and other secondary parkinsonisms. (c) Parkinsonian superposition syndrome including progressive supranuclear palsy, Lewy body dementia, and cortical basal ganglia degeneration. (d) Dysarthria and aphasia could not cooperate to complete the test. (e) Patients with complicated malignancy or other severe somatic diseases. (f) Patients with schizophrenia and affective mental disorders were combined. (g) Other diseases and drugs that can cause OH, such as diabetes mellitus, myocardial infarction, and drugs that can cause non-neurogenic OH, were excluded. (h) Nuclear exclusion excluded patients with brain atrophy at key sites. Key regions refer to brain areas associated with the pathophysiology of cognitive impairment, such as the frontal lobe and the medial temporal lobe (particularly the hippocampus). These regions are identified based on visual assessment or volumetric analysis of structural MRI scans (such as T1-weighted images), with reference to established radiological diagnostic criteria or age-matched normative data. Forty healthy volunteers with sex-and age-matching were included as a healthy control group, and the exclusion criteria were the same as above. Experimental design Group information The included PD patients were divided into two groups: those with OH and those without OH. Positive diagnostic criteria for OH [7]: When switching from supine to upright position for 3 min, systolic BP (SBP) decreased by 20 mmHg (1 mmHg = 0.133 kPa) and (or) diastolic BP (DBP) decreased by 10 mmHg, with or without dizziness. [20] Active standing test (AST) Conducted in a quiet, temperature-controlled room at 22–24 °C. All participants were fasted for>2 h after meals to minimize postprandial hypotension. Furthermore, they should avoid strenuous exercise and caffeine, and stop taking medications that affect the autonomic nervous system for at least 12 h, such as dopaminergic medications, antihypertensive drugs, and other medications. Blood pressure measurements were performed by asking the patient to rest for>10 min in the supine position. The patient was allowed to stand quickly and maintain the upright position for 5 min. If the patient has difficulty standing actively, the tester assisted the patient to stand quickly as fast as possible, and the patient should remain calm during the upright process. Blood pressure was measured in the supine, upright position at 1 min, 3 min and 5 min, and the cuff was always placed at the same height as the right heart. Data and methods The assessment of the condition and symptoms of PD patients is completed by a formally trained neurologist. Utilizing a self-designed scale, we gathered demographic details including gender, age, educational background, disease duration, onset symptoms, measurements of blood pressure in both supine and standing positions, internal medicine diseases (such as hypertension, diabetes, and medications regimens), familial medical history, the emergence of clinical signs, Levodopa equivalent dose (LEDD), and other pertinent data. The scale test includes Movement Disorder Society unified Parkinson's disease rating scale (MDS-UPDRS), Hoehn & Yahr scale (H&Y) and the PDQ-8 [21] scale, a simplified version of the PDQ-39. The diagnosis of Parkinson's disease – associated mild cognitive decline (PD - CD) was strictly in accordance with the Level 1 diagnostic criteria for PD - CD established by the Movement Disorder Society (MDS). All the patients who were enrolled had been diagnosed with primary Parkinson's disease in line with international standards (e.g., the MDS clinical diagnostic criteria). The Montreal Cognitive Assessment (MoCA), a concise global cognitive screening scale, was employed to assess patients. The patients' screening scores were compared with age-, education-, and culture-adjusted norms, and scores below a particular cut-off point (typically <26 for the MoCA) were used as the screening threshold. [22] We adjusted the raw MoCA scores of all participants based on their educational attainment. For instance, we added 1 point to the total score for those with 12 years of education or less. The classification differentiates between patients with normal cognitive function (PD - NC) and PD - CD according to a specific cut - off score. The latter group encompasses subjects with mild cognitive impairment and dementia. Supine-to-standing TCD Test Stop all nerve excitation and sleeping sedative for three days before examination, and take at least the day before examination. TCD can penetrate the thin parts of the skull and the natural pores to obtain the Doppler echo signals of the main arteries of the skull base. TCD examinations for recruiters were performed by the same professional technician, with final data exported from the equipment (ViasysNeurorare SONARA). All patients monitored cerebral blood flow in the horizontal position. TCD practitioners used TCD 2 MHz probe to detect unilateral or bilateral MCA-mCBFv through the temporal window of 50 to 60 mm in either MCA and fixed with a head cuff. Haemodynamic changes in the middle cerebral artery (MCA) provide the most accurate reflection of whole-brain perfusion and are highly sensitive to postural changes; furthermore, when detected via the temporal window, the MCA signal exhibits a high detection rate and good stability, making it the gold standard target vessel for TCD monitoring. Therefore, this study did not routinely incorporate other intracranial vessels, such as the anterior cerebral artery and posterior cerebral artery, for systematic analysis. The entire procedure involves asking the patient to lie flat for 3 min, then to quickly stand up and maintain an upright position for 5 min within 8 s, and finally to lie flat in the supine position for another 3 min. In consideration of the physiological mechanisms and the results of preliminary experiments, it is both reasonable and feasible to adopt a 3 - min supine period as the baseline. When a person from the horizontal position active stand, due to gravity, blood flows to the lower limbs and abdomen, resulting in a decrease in venous return and cardiac output, which leads to a drop in blood pressure. This is followed by a quick drop in cerebral blood flow speed to its lowest point, which then rebounds up to at least the supine baseline blood flow value, thereafter dropping again and stabilizing at a relatively constant speed. This process mCBFv curve forms a specific waveform on the TCD, known as the W spike. [17], [18] (Fig. 2).Fig. 2Dynamic transcranial Doppler (TCD) monitoring of the middle cerebral arteries(MCA) during supine-to-standing test.(A, D) Continuous spectral Doppler waveform of the MCA at a depth of 55 mm. The color bar indicates flow velocity (cm/s). (B, E) Instantaneous TCD hemodynamic parameters derived from the MCA tracing, including mean cerebral blood flow velocity (mCBFv), peek cerebral blood flow velocity (pCBFv), End-Diastolic Velocity (EDV), Pulsatility Index (PI), Resistive Index (RI), Systolic/Diastolic ratio (S/D) and Heart Rate (HR). (C, F) Trend graphs of key hemodynamic parameters (mCBFv, pCBFv, PI, HR) over time. Panel C demonstrates the characteristic “W spike”, a transient surge in flow velocity following postural change, indicative of an intact cerebrovascular autoregulatory response. Panel F shows the poor response of the W spike, signifying an impaired or absent compensatory vasoconstriction, which is associated with dysfunction in cerebrovascular autoregulation and/or the autonomic nervous system.Abbreviations: TCD, transcranial Doppler; MCA, middle cerebral artery; mCBFv, mean cerebral blood flow velocity; pCBFv, peak cerebral blood flow velocity; EDV, end-diastolic velocity; PI, Pulsatility index; RI, resistive index; S/D, systolic/diastolic ratio; HR, heart rateFig. 2 Dynamic transcranial Doppler (TCD) monitoring of the middle cerebral arteries(MCA) during supine-to-standing test. (A, D) Continuous spectral Doppler waveform of the MCA at a depth of 55 mm. The color bar indicates flow velocity (cm/s). (B, E) Instantaneous TCD hemodynamic parameters derived from the MCA tracing, including mean cerebral blood flow velocity (mCBFv), peek cerebral blood flow velocity (pCBFv), End-Diastolic Velocity (EDV), Pulsatility Index (PI), Resistive Index (RI), Systolic/Diastolic ratio (S/D) and Heart Rate (HR). (C, F) Trend graphs of key hemodynamic parameters (mCBFv, pCBFv, PI, HR) over time. Panel C demonstrates the characteristic “W spike”, a transient surge in flow velocity following postural change, indicative of an intact cerebrovascular autoregulatory response. Panel F shows the poor response of the W spike, signifying an impaired or absent compensatory vasoconstriction, which is associated with dysfunction in cerebrovascular autoregulation and/or the autonomic nervous system. Abbreviations: TCD, transcranial Doppler; MCA, middle cerebral artery; mCBFv, mean cerebral blood flow velocity; pCBFv, peak cerebral blood flow velocity; EDV, end-diastolic velocity; PI, Pulsatility index; RI, resistive index; S/D, systolic/diastolic ratio; HR, heart rate We collected measurements of mean cerebral blood flow velocity (mCBFv) and pulsatility index (PI) at the lowest point, as well as in the 1st, 3rd, and 5th minutes of both the supine baseline and upright positions using TCD. Blood pressure and heart rate were also measured at the above time points. The whole inspection process is required to be completed within 15 min, in order to observe the appearance of various waveforms and the change of the flow rate. In this test, if rebound mCBFv did not reach supine baseline level within 30 s after standing, we defined it as incomplete “W spike” callback. Two neurologists independently reached conclusions (regarding the presence or absence of the W spike). (Fig. 2). QASAT The QASAT Score Scale [23], an objective tool for grading autonomic dysfunction, associated small fiber neuropathy, and cerebral blood flow, evaluates the degree of cerebral blood velocity decline during orthostatic processes, considered to have OCHO [12] at orthostatic velocity score > 1. Calculation of orthostatic cerebral blood flow velocity score: Baseline blood flow is defined as 100%, with a value of 0 assigned. The ratio of the lowest mCBFv within 30 s of standing to the baseline in the supine position was defined as MIN mCBFvR (% of baseline). By analogy, we get 1 min mCBFvR, 3 min mCBFvR and 5 min mCBFvR. A normal 1 min mCBFvR should be ≥90%. Assign a score of 1 for ratio 80–90%, 2 for 70–80%, and 3 for <70%. At 5 min: a normal mCBFvR is ≥89%. Assign a score of 1 for 79–89%, 2 for 69–79%, and 3 for <69%. The total score is the sum of the scores at 1 and 5 min. During the trial, patients were inquired about experiencing dizziness and dark symptoms. Patients were grouped based on the results of horizontal blood pressure and orthostatic cerebral blood flow velocity scores. Examine the correlation between the PD with OH group and the disappearance of W spike, OCHO, alongside cognitive Impairment. Statistical analysis All data in this study were analyzed and processed using SPSS 25.0 statistical software. First, Shapiro-Wilk test follows the normal distribution, and independent sample t-test is used as the mean ± standard deviation (x ± s); without the normal distribution, Mann-Whitney U test is used as the median and quartile centile [M (P25, P75)]. For the count data, the Pearson chi-square test or Fisher's exact probability test was used. To assess the diagnostic consistency between two observers in the presence of W spikes, we calculated the Cohen's Kappa coefficient. Statistically significant relevant clinical factors were selected by the above univariate analysis and further using multivariate Logistic regression analysis, P < 0.05 was considered statistically significant. The construction of multivariate regression models adheres to the following principles. Firstly, all variables that possess clear biological or clinical relevance and are known or suspected to have an impact on the study outcomes (e.g., TCD parameters or cognitive function) must be included, regardless of whether the differences between groups were significant in univariate analysis. On this basis, statistical methods such as forward or backward stepwise regression are then employed to identify variables with independent predictive power. To evaluate the independent association between OH and cerebral vascular parameters measured by TCD, a multivariate regression analysis was conducted. The outcome variables were the key TCD parameters, namely 1 min mCBFvR, 3 min mCBFvR, and 5 min mCBFvR. The primary predictor variable was OH, which was a binary variable (yes/no). The adjusted confounding factors were pre - determined based on clinical relevance and included: model 1 (demographic model): age and gender; model 2 (extended clinical model): disease duration, H&Y and UPDRS III score; model 3 (haemodynamic model): mean arterial pressure (MAP, supine), heart rate (HR, supine) and WD. The regression results are presented as adjusted β coefficients (or mean differences), 95% confidence intervals, and p - values. Linear regression combined with the Bootstrap method (utilizing the PROCESS macro, with the number of Bootstrap samples set to 5000) will be employed to test the mediating effect of TCD parameters in the relationship between OH and cognitive function. An analysis of missing data indicated that the missing value rates of the primary independent variables were all below 5%, which was in line with the characteristics of randomly missing data. A comprehensive case analysis was conducted on the core variables, while multiple imputation methods were employed for covariates with missing values. To improve statistical power and make full use of all available information, five complete datasets were generated through chain - linking. Following the imputation process, all variables exhibited no missing values. Results Demographic data and clinical characteristics of PD and normal controls(NC) A total of 96 PD patients and 40 healthy patients were included in the study for the analysis, and the demographic data and clinical characteristics are summarized in Table 1. Following the TCD screening, 31 patients with poor temporal window penetration were excluded. A systematic comparison was conducted of the baseline characteristics between the ‘TCD completion group’ and the ‘TCD failure group’. The results of the analysis (refer to Supplementary Table 1 for details) showed that there were no significant differences between the two groups in any of the key baseline characteristics. 65 individuals with PD (mean age, 64.06 ± 6.79 years; 39 males and 26 females) and 40 healthy control subjects (mean age, 61.83 ± 12.11 years; 20 males and 20 females) successfully underwent the TCD test in both supine and standing positions. 28 PD patients had cognitive decline and 37 had normal cognition.Table 1Demographic data and clinical characteristics of the PD group and the HC group.PDn = 65HCn = 40T value / chi-square valueP-valueAge (years)64.06 ± 6.7961.83 ± 12.11−0.7490.31Gender a (Male %)55.4%(39)50%(20)0.5780.447Education b (years)9(6,12)9(9,12)–0.244BMI(kg/m2)23.57 ± 3.3322.91 ± 2.39−7.870.434MAP(mmHg)94.52 ± 8.4190.54 ± 6.49−1.8570.067SBP(mmHg)127.49 ± 12.32123.5 ± 10.43−1.2540.213DBP(mmHg)77.95 ± 7.9374.06 ± 5.94−1.9370.056HR73.02 ± 8.7172.28 ± 6.65−0.3330.74mCBFv(cm/s)39.08 ± 12.0233.43 ± 9.27−1.8470.068PI1.03 ± 0.230.96 ± 0.21−1.0670.289MoCA24.62 ± 3.29627.83 ± 1.254.133***PD, Parkinson's disease; HC, healthy controls; BMI, Body Mass Index; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; mCBFv, mean Cerebral Blood Flow velocity,baseline; PI, pulsitility index; MoCA, Montreal cognitive assessment.arepresented as Chi-square test.brepresented as Mann-Whitney U test.***represented as p < 0.001. P < 0.05 was considered statistically significant. Table 1Demographic data and clinical characteristics of the PD group and the HC group.PDn = 65HCn = 40T value / chi-square valueP-valueAge (years)64.06 ± 6.7961.83 ± 12.11−0.7490.31Gender a (Male %)55.4%(39)50%(20)0.5780.447Education b (years)9(6,12)9(9,12)–0.244BMI(kg/m2)23.57 ± 3.3322.91 ± 2.39−7.870.434MAP(mmHg)94.52 ± 8.4190.54 ± 6.49−1.8570.067SBP(mmHg)127.49 ± 12.32123.5 ± 10.43−1.2540.213DBP(mmHg)77.95 ± 7.9374.06 ± 5.94−1.9370.056HR73.02 ± 8.7172.28 ± 6.65−0.3330.74mCBFv(cm/s)39.08 ± 12.0233.43 ± 9.27−1.8470.068PI1.03 ± 0.230.96 ± 0.21−1.0670.289MoCA24.62 ± 3.29627.83 ± 1.254.133***PD, Parkinson's disease; HC, healthy controls; BMI, Body Mass Index; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; mCBFv, mean Cerebral Blood Flow velocity,baseline; PI, pulsitility index; MoCA, Montreal cognitive assessment.arepresented as Chi-square test.brepresented as Mann-Whitney U test.***represented as p < 0.001. P < 0.05 was considered statistically significant. Demographic data and clinical characteristics of the PD group and the HC group. PD, Parkinson's disease; HC, healthy controls; BMI, Body Mass Index; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; mCBFv, mean Cerebral Blood Flow velocity,baseline; PI, pulsitility index; MoCA, Montreal cognitive assessment. represented as Chi-square test. represented as Mann-Whitney U test. represented as p < 0.001. P < 0.05 was considered statistically significant. Patients with PD were compared with healthy control (HC) subjects, wherein no statistically significant differences were observed with respect to age, gender, body mass index (BMI), years of education, baseline supine blood pressure, baseline heart rate, and baseline mCBFv, as well as the PI (P > 0.05). However, the MoCA scores in PD patients was significantly lower than those in the HC group (P < 0.001). Comparison of PD subgroups with or without OH Demographic data and clinical data Patients diagnosed with PD were categorized into two groups based on the results of the AST test: the PD-OH group and the PD-NOH group. Within this cohort, 24 individuals exhibited positive signs of OH. Upon statistical analysis, it was found that the PD-OH group had higher age, H&Y, disease duration, total LEDD, and MoCA scores compared to the PD-NOH group, with statistical significance (P < 0.05) (Table 2). This is consistent with the findings [24] that PD-OH patients exhibit more severe disease progression and cognitive Impairment, as indicated by the higher age, longer disease duration, and lower cognitive function scores compared to the PD-NOH group. Two groups were well–balanced in gender, BMI, age of onset, prevalence, proportion of PIGD typing, and MDS-UPDRS III score (p > 0.05).Table 2Demographic data and clinical characteristics of PD with or without OH and CD.PD-NOHn = 41PD-OHn = 24P-valuePD-NCn = 37PD-CDn = 28P-valueAge (y)62.17 ± 5.7466.04 ± 6.40.014⁎61.89 ± 6.4265.86 ± 5.280.01⁎Male a (%)51.2 (21)75(18)0.05978.4(29)67.9(19)0.261Education b (y)9(9,12)9(6.75,15)0.9439(9,14)9(6,12)0.17BMI(kg/m2)23.82 ± 2.8823.14 ± 4.030.43523.638 ± 2.9823.48 ± 3.810.853Hypertension a (%)24.4 (10)12.5 (3)0.24710.8(4)32.1(9)0.033⁎Disease Duration b (y)4(3,6)7(6,9)***4(2.5,5.5)8(6,10)***Age of Onset (y)58.25 ± 7.0357.1 ± 5.900.48257.95 ± 6.7256.96 ± 5.810.539PDQ-84.52 ± 5.575.32 ± 3.80.5814.13 ± 4.75.9 ± 5.310.214MDS UPDRS III34.72 ± 15.542.91 ± 22.80.10933.88 ± 17.4843.42 ± 19.650.057H&Y b2(1,3)2(2,3.125)0.016⁎2(1,2)2.25(2,3.375)0.005⁎⁎PIGD(%)a51.2(21)54.2(13)0.45551.9(19)85.7(15)0.013⁎LEDD363.48 ± 230.92738.3 ± 445.640.002⁎⁎332.95 ± 226.29781.05 ± 405.67***MoCA25.71 ± 2.0522.75 ± 4.140.003⁎⁎27.55 ± 1.50820.39 ± 4.008***CD(%)24.3(10)75(18)***Poor W spike Correction (%)14.6(6)87.5(21)***18.9(7)71.4(20)***OCHO(%)51.2(21)95.8(23)***54.1(20)82.1(23)0.018⁎⁎OH Symptoms(%)12.2(5)62.5 (15)***7.9(3)60.7(17)***PD-OH, Parkinson's disease with orthostatic hypotension; PD-NOH, Parkinson's disease with non-orthostatic hypotension; PD-CD, Parkinson's disease with cognitive decline; PD-NC, Parkinson's disease with normal cognition; BMI, body mass index; PDQ-8, a simplified version of the PDQ-39 scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; H&Y, Hoehn & Yahr stage; PIGD, postural instability and gait difficulty; LEDD, Levodopa equivalent dose; MoCA, Montreal Cognitive Assessment; OCHO, orthostatic cerebral hypoperfusion.arepresented as Chi-square test. Table 2Demographic data and clinical characteristics of PD with or without OH and CD.PD-NOHn = 41PD-OHn = 24P-valuePD-NCn = 37PD-CDn = 28P-valueAge (y)62.17 ± 5.7466.04 ± 6.40.014⁎61.89 ± 6.4265.86 ± 5.280.01⁎Male a (%)51.2 (21)75(18)0.05978.4(29)67.9(19)0.261Education b (y)9(9,12)9(6.75,15)0.9439(9,14)9(6,12)0.17BMI(kg/m2)23.82 ± 2.8823.14 ± 4.030.43523.638 ± 2.9823.48 ± 3.810.853Hypertension a (%)24.4 (10)12.5 (3)0.24710.8(4)32.1(9)0.033⁎Disease Duration b (y)4(3,6)7(6,9)***4(2.5,5.5)8(6,10)***Age of Onset (y)58.25 ± 7.0357.1 ± 5.900.48257.95 ± 6.7256.96 ± 5.810.539PDQ-84.52 ± 5.575.32 ± 3.80.5814.13 ± 4.75.9 ± 5.310.214MDS UPDRS III34.72 ± 15.542.91 ± 22.80.10933.88 ± 17.4843.42 ± 19.650.057H&Y b2(1,3)2(2,3.125)0.016⁎2(1,2)2.25(2,3.375)0.005⁎⁎PIGD(%)a51.2(21)54.2(13)0.45551.9(19)85.7(15)0.013⁎LEDD363.48 ± 230.92738.3 ± 445.640.002⁎⁎332.95 ± 226.29781.05 ± 405.67***MoCA25.71 ± 2.0522.75 ± 4.140.003⁎⁎27.55 ± 1.50820.39 ± 4.008***CD(%)24.3(10)75(18)***Poor W spike Correction (%)14.6(6)87.5(21)***18.9(7)71.4(20)***OCHO(%)51.2(21)95.8(23)***54.1(20)82.1(23)0.018⁎⁎OH Symptoms(%)12.2(5)62.5 (15)***7.9(3)60.7(17)***PD-OH, Parkinson's disease with orthostatic hypotension; PD-NOH, Parkinson's disease with non-orthostatic hypotension; PD-CD, Parkinson's disease with cognitive decline; PD-NC, Parkinson's disease with normal cognition; BMI, body mass index; PDQ-8, a simplified version of the PDQ-39 scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; H&Y, Hoehn & Yahr stage; PIGD, postural instability and gait difficulty; LEDD, Levodopa equivalent dose; MoCA, Montreal Cognitive Assessment; OCHO, orthostatic cerebral hypoperfusion.arepresented as Chi-square test. Demographic data and clinical characteristics of PD with or without OH and CD. PD-OH, Parkinson's disease with orthostatic hypotension; PD-NOH, Parkinson's disease with non-orthostatic hypotension; PD-CD, Parkinson's disease with cognitive decline; PD-NC, Parkinson's disease with normal cognition; BMI, body mass index; PDQ-8, a simplified version of the PDQ-39 scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; H&Y, Hoehn & Yahr stage; PIGD, postural instability and gait difficulty; LEDD, Levodopa equivalent dose; MoCA, Montreal Cognitive Assessment; OCHO, orthostatic cerebral hypoperfusion. represented as Chi-square test. Comparison of changes in BP, heart rate, and cerebral hemodynamics parameters measured by TCD in supine and standing positions There was no significant difference in the baseline cerebral hemodynamics of PD patients with or without OH in the supine position. (p > 0.05) (Supporting information 1). In the PD-OH group, the MAP, SBP, and DBP were significantly lower than those in the PD-NOH group, with a statistically significant difference (p < 0.05). Notably, the mean SBP change at the 1-min mark upon standing was (21.83 ± 13.69) mmHg. Subsequently, at the 3-min and 5-min intervals post-standing, the change diminished in comparison to the 1-min mark; nonetheless, it remained significantly elevated relative to the PD-NOH cohort. The mCBFv and PI of the PD-OH group at any time point showed no significant difference compared to the PD-NOH group (p > 0.05). However, according to the calculations by QASAT, the baseline blood flow in the supine position is defined as 100%, and the PD-OH group shows a significant decrease in blood flow velocity as a percentage at the 1st, 3rd, and 5th minutes in the standing position. (p < 0.001) (Supporting information 2). The role of the poor W spike response in the OH According to the characteristics of blood pressure and cerebral hemodynamic W spike change during supine-to-standing TCD test, PD patients were divided into four groups: OH-W group: OH with W spike presence; OH-WD group: OH with W spike disappearance; WD group: simple W spike disappeared without OH; and normal response group. According to the analysis of variance, there was no significant difference in the gender, MIN mCBFvR, MDS-UPDRS III score, PDQ-8, and PIGD categories between the four groups (P > 0.05) (Table 3). In this study, the Kappa value of 0.833 indicates that our scoring criteria exhibit good reproducibility.Table 3TCD Parameters in PD with or without OH and Poor W spike Correction.aOH-W Groupn = 3OH-WD Groupn = 21WD Groupn = 6Normal Response Groupn = 35P-valueAge (years)59 ± 8.5467.05 ± 5.60c63.33 ± 4.5061.97 ± 5.950.012⁎Gender a (Male %)100(3)71.4(15)33.3(2)54.3(19)0.145Disease Duration b (years)57(6,9)6(4,10)4(3,6)0.000⁎⁎H&Y b23(2,3)2(1,2)2(1,2)0.031⁎MDS UPDRS III27 ± 24.2745.42 ± 22.1928.83 ± 10.3835.9 ± 16.200.122LEDD (mg)386.67 ± 183.46800.35 ± 452.05 c350 ± 377.49 d365.1 ± 219.290.001⁎⁎Min mCBFvR (%)92.68 ± 14.9276.36 ± 10.51 c81.13 ± 11.9081.2 ± 11.770.1243 min mCBFvR (%)86.29 ± 9.74d75.65 ± 7.05 c79.6 ± 8.03 c90.36 ± 6.79***OCHO a (%)50(1)100(21)100(6)42.9(15)***QASAT Score1.33 ± 2.31d3.71 ± 1.31 c2.33 ± 1.03 cd0.71 ± 0.99***MoCA24 ± 5.222.57 ± 4.1 c25.5 ± 1.05 d25.74 ± 2.190.003⁎⁎CD a (%)33.3 (1)81(17)50(3)20(7)***PDQ-85 ± 6.935.38 ± 3.303.6 ± 3.284.68 ± 5.920.918The incidence of dizziness a (%)071.4(15)50(3)5.7(2)***PIGD a (%)33.3(1)52.4(11)33.3(2)51.4(18)0.255OH-W, Orthostatic hypotension with the W spike; OH-WD, Orthostatic hypotension with the W spike disappearance; WD, the W spike disappearance; H&Y, Hoehn & Yahr scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; LEDD, Levodopa equivalent dose; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; OCHO, orthostatic cerebral hypoperfusion; QASAT, Quantitative Autonomic Reflex and Small Fibers Tests; MoCA, Montreal Cognitive Assessment; CD, cognitive decline; PDQ-8, a simplified version of the PDQ-39 scale; PIGD, postural instability and gait difficulty.arepresented as Chi-square test.brepresented as Kruskal-Wallis H test. Table 3TCD Parameters in PD with or without OH and Poor W spike Correction.aOH-W Groupn = 3OH-WD Groupn = 21WD Groupn = 6Normal Response Groupn = 35P-valueAge (years)59 ± 8.5467.05 ± 5.60c63.33 ± 4.5061.97 ± 5.950.012⁎Gender a (Male %)100(3)71.4(15)33.3(2)54.3(19)0.145Disease Duration b (years)57(6,9)6(4,10)4(3,6)0.000⁎⁎H&Y b23(2,3)2(1,2)2(1,2)0.031⁎MDS UPDRS III27 ± 24.2745.42 ± 22.1928.83 ± 10.3835.9 ± 16.200.122LEDD (mg)386.67 ± 183.46800.35 ± 452.05 c350 ± 377.49 d365.1 ± 219.290.001⁎⁎Min mCBFvR (%)92.68 ± 14.9276.36 ± 10.51 c81.13 ± 11.9081.2 ± 11.770.1243 min mCBFvR (%)86.29 ± 9.74d75.65 ± 7.05 c79.6 ± 8.03 c90.36 ± 6.79***OCHO a (%)50(1)100(21)100(6)42.9(15)***QASAT Score1.33 ± 2.31d3.71 ± 1.31 c2.33 ± 1.03 cd0.71 ± 0.99***MoCA24 ± 5.222.57 ± 4.1 c25.5 ± 1.05 d25.74 ± 2.190.003⁎⁎CD a (%)33.3 (1)81(17)50(3)20(7)***PDQ-85 ± 6.935.38 ± 3.303.6 ± 3.284.68 ± 5.920.918The incidence of dizziness a (%)071.4(15)50(3)5.7(2)***PIGD a (%)33.3(1)52.4(11)33.3(2)51.4(18)0.255OH-W, Orthostatic hypotension with the W spike; OH-WD, Orthostatic hypotension with the W spike disappearance; WD, the W spike disappearance; H&Y, Hoehn & Yahr scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; LEDD, Levodopa equivalent dose; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; OCHO, orthostatic cerebral hypoperfusion; QASAT, Quantitative Autonomic Reflex and Small Fibers Tests; MoCA, Montreal Cognitive Assessment; CD, cognitive decline; PDQ-8, a simplified version of the PDQ-39 scale; PIGD, postural instability and gait difficulty.arepresented as Chi-square test.brepresented as Kruskal-Wallis H test. TCD Parameters in PD with or without OH and Poor W spike Correction.a OH-W, Orthostatic hypotension with the W spike; OH-WD, Orthostatic hypotension with the W spike disappearance; WD, the W spike disappearance; H&Y, Hoehn & Yahr scale; MDS UPDRS, Movement Disorder Society unified Parkinson's disease rating scale; LEDD, Levodopa equivalent dose; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; OCHO, orthostatic cerebral hypoperfusion; QASAT, Quantitative Autonomic Reflex and Small Fibers Tests; MoCA, Montreal Cognitive Assessment; CD, cognitive decline; PDQ-8, a simplified version of the PDQ-39 scale; PIGD, postural instability and gait difficulty. represented as Chi-square test. represented as Kruskal-Wallis H test. The disease course in the OH-WD group was significantly longer than that in the normal response group. The lowest mCBFv proportion within 30s in the OH-WD group was significantly lower than that in the OH-W group (P < 0.05). However, the 3 min mCBFvR in the OH-WD group was significantly lower than that in the W spike presence group, regardless of whether OH was combined (P < 0.05). Simultaneously, whether accompanied by OH or not, the 3 min mCBFvR in the W spike poor response group is less than that in the normal response group (P < 0.05). Regarding the QASAT scores and the LEDD, the OH-WD group exhibited significantly higher values than those in the other three groups. Among these, the presence of OH with or without wave correction was markedly elevated compared to the group with normal reactions. (P < 0.05). The incidence of OCHO in the W spike disappearence group was 100%, significantly higher than that in the existence of W spike group (P < 0.05). MoCA scores and the incidence of CD were notably higher in the OH-WD group compared to the WD and normal response groups. Independent correlation between OH and cerebrovascular parameters measured by TCD In the multiple linear regression analysis, it was observed that OH has a dynamic impact on 5 min mCBFvR, while no significant changes were detected at 1-min and 3-min intervals. In the baseline model adjusted solely for demographic factors, OH was significantly correlated with a reduction in MFV (β = −0.47, p = 0.048). Nevertheless, when the model was further adjusted for disease severity indicators (duration of illness, H – Y staging, and UPDRS - III score), this correlation was no longer significant (β = −0.47, p = 0.069), indicating that the initial correlation was mainly confounded by disease progression. Remarkably, when immediate haemodynamic parameters (MAP, HR, and WD) were ultimately incorporated into the model, the independent correlation between OH and reduced MFV reappeared and achieved statistical significance (β = −0.54, p = 0.029). In Model 3, OH, MAP and WD were identified as independent factors influencing TCD data. (Table 4).Table 4Multivariate linear regression analysis of the association between OH and TCD parameters.Model 1Model 2Model 3βPβPβPOH−0.47(−24.49, −0.11)0.048−0.47(−26.08, 1.16)0.069−0.54(−26.50, −1.86)0.029Age0.15(−0.57, 1.08)0.5150.19(−0.65, 1.33)0.469−0.12(−0.71, 1.12)0619Gender−0.24(−18.61, 6.19)0.303−0.28(−21.21, 6.26)0.258−0.04(−14.52, 12.42)0.865UPDRS III−0.17(−0.56, 0.32)0.575−0.19(−0.56, 0.29)0.492H & Y−0.17(−17.12, 10.96)0.641−0.14(−15.89, 10.82)0.677Disease Duration−0.05(−3.55, 3.15)0.896−0.05(−3.08, 2.63)0.862MAP0.57(0.06, 1.48)0.037HR0.15(−0.57, 0.99)0.557WD−0.45(−25.92, −0.14)0.048 Model statisticsR20.320.430.72F2.31.52.5OH, orthostatic hypotension; TCD transcranial Doppler; UPDRS III, unified Parkinson's Disease Rating Scale Part three; H & Y, Hoehn & Yahr stage; MAP, mean arterial pressure; HR, heart rate; WD, W spike disappearance. R2, Overall model fit; F, Model overall significance. Table 4Multivariate linear regression analysis of the association between OH and TCD parameters.Model 1Model 2Model 3βPβPβPOH−0.47(−24.49, −0.11)0.048−0.47(−26.08, 1.16)0.069−0.54(−26.50, −1.86)0.029Age0.15(−0.57, 1.08)0.5150.19(−0.65, 1.33)0.469−0.12(−0.71, 1.12)0619Gender−0.24(−18.61, 6.19)0.303−0.28(−21.21, 6.26)0.258−0.04(−14.52, 12.42)0.865UPDRS III−0.17(−0.56, 0.32)0.575−0.19(−0.56, 0.29)0.492H & Y−0.17(−17.12, 10.96)0.641−0.14(−15.89, 10.82)0.677Disease Duration−0.05(−3.55, 3.15)0.896−0.05(−3.08, 2.63)0.862MAP0.57(0.06, 1.48)0.037HR0.15(−0.57, 0.99)0.557WD−0.45(−25.92, −0.14)0.048 Model statisticsR20.320.430.72F2.31.52.5OH, orthostatic hypotension; TCD transcranial Doppler; UPDRS III, unified Parkinson's Disease Rating Scale Part three; H & Y, Hoehn & Yahr stage; MAP, mean arterial pressure; HR, heart rate; WD, W spike disappearance. R2, Overall model fit; F, Model overall significance. Multivariate linear regression analysis of the association between OH and TCD parameters. OH, orthostatic hypotension; TCD transcranial Doppler; UPDRS III, unified Parkinson's Disease Rating Scale Part three; H & Y, Hoehn & Yahr stage; MAP, mean arterial pressure; HR, heart rate; WD, W spike disappearance. R2, Overall model fit; F, Model overall significance. The relationship between the OH and the cognitive function Upon calculating the QASAT, it was observed that only one individual from the group of PD patients with concurrent OH did not manifest OCHO [23 (95.8%) versus 21 (51.2%), p < 0.001]. This finding was statistically significant. The incidence of CD in the PD group with OH [75% vs 24.3%, p < 0.001] was significantly higher than in the group without OH. The incidence of poor W spike correction, OCHO, and OH symptoms in the PD-CD group were significantly higher than those in the PD-NC group (p < 0.001) (Table 2 Demographic Data and Clinical Characteristics of PD with or without OH and Table 2). Due to the small sample size of hypertension, the statistical significance of the prevalence of hypertension was not credible. PD patients combined with CD exhibit a respective reduction in the upright position at 1st, 3rd, and 5th minutes mCBFvR compared to their corresponding control groups (Fig. 3).Fig. 3Cerebral hemodynamic parameters in upright position in PD with CD.CD, cognitive decline; NC, normal cognition; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; 5 min mCBFvR, mean cerebral blood flow velocity ratio at 5th minute of tilt,% of baseline.⁎⁎ represented as p < 0.01. ⁎⁎⁎ represented as p < 0.00. P < 0.05 was considered statistically significant.Fig. 3 Cerebral hemodynamic parameters in upright position in PD with CD. CD, cognitive decline; NC, normal cognition; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; 5 min mCBFvR, mean cerebral blood flow velocity ratio at 5th minute of tilt,% of baseline. ⁎⁎ represented as p < 0.01. ⁎⁎⁎ represented as p < 0.00. P < 0.05 was considered statistically significant. The resultant indicates that mCBFvR exhibits a slight positive correlation with MoCA scores. This suggests that diminished cerebral blood flow is associated with a marginal exacerbation of cognitive impairments. (Table 5).Table 5Correlation analysis between MoCA and CBFv.MoCAcorrelation coefficientP-valuedegree of correlation1 min mCBFvR0.3380.006⁎⁎Weak positive3 min mCBFvR0.3270.008⁎⁎weak positive5 min mCBFvR0.2910.019⁎⁎weak positiveSBP change−0.4080.001⁎⁎weak negativeMoCA, Montreal Cognitive Assessment; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; 5 min mCBFvR, mean cerebral blood flow velocity ratio at 5th minute of tilt,% of baseline; SBP, systolic blood pressure.⁎⁎represented as p < 0.01. P < 0.05 was considered statistically significant. Table 5Correlation analysis between MoCA and CBFv.MoCAcorrelation coefficientP-valuedegree of correlation1 min mCBFvR0.3380.006⁎⁎Weak positive3 min mCBFvR0.3270.008⁎⁎weak positive5 min mCBFvR0.2910.019⁎⁎weak positiveSBP change−0.4080.001⁎⁎weak negativeMoCA, Montreal Cognitive Assessment; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; 5 min mCBFvR, mean cerebral blood flow velocity ratio at 5th minute of tilt,% of baseline; SBP, systolic blood pressure.⁎⁎represented as p < 0.01. P < 0.05 was considered statistically significant. Correlation analysis between MoCA and CBFv. MoCA, Montreal Cognitive Assessment; MIN mCBFvR; minimum mean cerebral blood flow velocity ratio, % of baseline; 3 min mCBFvR, mean cerebral blood flow velocity ratio at 3rd minute of tilt,% of baseline; 5 min mCBFvR, mean cerebral blood flow velocity ratio at 5th minute of tilt,% of baseline; SBP, systolic blood pressure. represented as p < 0.01. P < 0.05 was considered statistically significant. When the mediator variable 5 – minute mean cerebral blood flow velocity ratio (5 min mCBFvR) was not taken into account, the coefficient of the overall effect of OH on the MoCA score was negative and statistically significant (effect = − 3.6113; p = 0.0004). After controlling for the 5 min mCBFvR, the direct effect of OH on the MoCA score remained significant; however, the effect size (− 3.23) was smaller than the total effect (− 3.61). (Table 6).Table 6Results of mediating effect analysis on the impact of OH on cognitive function through TCD parameters.Effect typeEffectse/BootSEtp(LLCI,ULCI)Total Effect−3.61130.9664−3.73700.0004[−5.5430, −1.6795]Direct Effect−3.23090.9829−3.28710.0017[−5.1963, −1.2654]Indirect Effect−0.38040.3610––[−1.3106, 0.0542]Partial standardized indirect effects−0.09180.0893––[−0.3277, 0.0129]se, Standard Error; BootSE, Bootstrap Standard Error; LLCI, Lower Limit Confidence Interval; ULCI, Upper Limit Confidence Interval. Table 6Results of mediating effect analysis on the impact of OH on cognitive function through TCD parameters.Effect typeEffectse/BootSEtp(LLCI,ULCI)Total Effect−3.61130.9664−3.73700.0004[−5.5430, −1.6795]Direct Effect−3.23090.9829−3.28710.0017[−5.1963, −1.2654]Indirect Effect−0.38040.3610––[−1.3106, 0.0542]Partial standardized indirect effects−0.09180.0893––[−0.3277, 0.0129]se, Standard Error; BootSE, Bootstrap Standard Error; LLCI, Lower Limit Confidence Interval; ULCI, Upper Limit Confidence Interval. Results of mediating effect analysis on the impact of OH on cognitive function through TCD parameters. se, Standard Error; BootSE, Bootstrap Standard Error; LLCI, Lower Limit Confidence Interval; ULCI, Upper Limit Confidence Interval. The confidence interval in this case is [−1.3106, 0.0542], which contains zero. This implies that the mediating role of 5-min mCBFvR between OH and MoCA is not significant, even though the point estimate of the indirect effect is also negative (−0.3804). Likewise, the confidence interval [−0.3277, 0.0129] still includes zero, further validating that the standardized mediation effect remains non - significant. Risk factor analysis of cognitive deficit in PD patients Based on Table 2, it was observed that patients with PD-CD had higher average age, longer disease duration, more advanced H&Y stages, greater total LEDD scores, and lower MoCA scores compared to the PD-NC group (P < 0.05). A significant proportion, specifically 85.7%, of patients diagnosed with CD in the context of PD exhibited the PIGD subtype (p = 0.013). And there were no statistically significant differences between the two groups in terms of gender, BMI, age of onset, and MDS-UPDRS III scores. (P > 0.05).(Table 7).Table 7Risk Factors for Cognitive Impairment in PD.Model 1Model 2OR(95%CI)POR(95%CI)PAge1.122(1.023–1.232)0.015⁎1.108(0.934–1.314)0.754Disease Duration2.96(1.661–5.273)<0.001⁎⁎⁎1.354(0.757–2.425)0.048⁎Education (years)0.891(0.762–1.041)0.1470.795(0.619–1.021)0.116LEDD1.006(1.002–1.01)0.002⁎⁎1.001(0.997–1.005)0.132With OH9.3(2.895–29.873)<0.001⁎⁎⁎0.619(0.074–5.195)0.412OR: odds ratio, CI: confidence interval, LEDD, levodopa equivalent daily dose; OH: orthostatic hypotension; *: p < 0.05; * * p < 0.01, * * * p < 0.05. Table 7Risk Factors for Cognitive Impairment in PD.Model 1Model 2OR(95%CI)POR(95%CI)PAge1.122(1.023–1.232)0.015⁎1.108(0.934–1.314)0.754Disease Duration2.96(1.661–5.273)<0.001⁎⁎⁎1.354(0.757–2.425)0.048⁎Education (years)0.891(0.762–1.041)0.1470.795(0.619–1.021)0.116LEDD1.006(1.002–1.01)0.002⁎⁎1.001(0.997–1.005)0.132With OH9.3(2.895–29.873)<0.001⁎⁎⁎0.619(0.074–5.195)0.412OR: odds ratio, CI: confidence interval, LEDD, levodopa equivalent daily dose; OH: orthostatic hypotension; *: p < 0.05; * * p < 0.01, * * * p < 0.05. Risk Factors for Cognitive Impairment in PD. OR: odds ratio, CI: confidence interval, LEDD, levodopa equivalent daily dose; OH: orthostatic hypotension; *: p < 0.05; * * p < 0.01, * * * p < 0.05. In line with the findings of this study, a single regression analysis was conducted that included age, years of education, disease duration, OH, and LEDD. The analysis revealed that longer disease duration (odds ratio [OR] = 2.96, 95% confidence interval [CI] 1.661 to 5.273), advanced age, higher LEDD, and OH (OR = 9.3, CI 2.895 to 29.873) were positively correlated with the presence of CD in PD patients. This suggests that PD patients with longer disease duration, older age, higher daily total LEDD doses, or OH are at a higher risk of developing CD (Model 1, Table 7). In the multifactorial analysis, the disease course remains positively correlated with cognitive Impairment (OR = 1.354, P = 0.048, Model 2, Table 7). Age, years of education, LEDD, and the presence of OH are no longer considered risk factors for CD. Discussion Using dynamic TCD monitoring, this study systematically investigated the complex relationship between OH, cerebral autoregulation and cognitive impairment in patients with PD. Our key findings provide new insights into the haemodynamic mechanisms underlying cognitive decline in PD patients. Our study indicates that OH is a significant factor associated with CD in PD, but its direct impact may be limited. This study first confirmed the high prevalence of CD in patients with PD-OH (75%). Moreover, OH is a single-factor risk factor for cognitive decline in PD patients(OR = 9.3). This is consistent with previous studies, indicating that OH is a significant marker of disease progression and cognitive impairment in PD. However, in multivariate regression analysis, after adjusting for other covariates such as disease duration and severity, the independent association between OH itself and CD was no longer statistically significant. This finding suggests that the association between OH and cognitive impairment may not be a direct causal relationship, but rather that both reflect a more advanced, diffuse disease process. OH may serve as a “marker” of the overall burden of the disease, rather than being the sole direct cause of cognitive impairment. The prevalence of the disease, OH, is high. In our study, 24 (25%) of 96 PD patients were found to be positive by active standing test, which was consistent with the incidence reported in pertinent literature (range: 10%–65%). [12], [25] And it increases as the disease progresses. A meta-analysis and additional studies have indicated that the prevalence of OH in PD patients ranges from 30.1% to 46.7%. [1] Due to its diverse and often nonspecific clinical manifestations, it is frequently not diagnosed until later stages of the clinical course. A meta-analysis of prospective studies have indicated that OH is associated with a 1.5-fold increase in all-cause mortality over a 5-year period. In PD patients with OH, the mortality rate was 2.4 times higher compared to patients without OH. [6], [26] A relatively substantial number of participants were excluded because of unfavorable temporal window conditions. Nevertheless, a comparison of the baseline data indicates that the study results are not affected by significant selection bias. OH has been demonstrated to result in impaired cerebral blood supply. Chronic hypoxia, which is secondary to recurrent cerebral hypoperfusion, is widely dregarded as factor to cognitive impairment by exacerbating vasculopathy and neurodegeneration. The link between the severity of OH and cognitive decline is still being debated. [27], [28] After degree by OH severity, [29] no significant differences in cognitive function were observed between groups (Supporting Information 5). This may primarily result from insufficient statistical power due to reduced sample size post-stratification. According to the other data of this study, SBP change, as a measure of the severity of OH, was negatively correlated with MoCA. The less SBP decreased, the lower the MoCA score was. However, the correlation is tenuous. It is evident from the lateral perspective that the intensity of OH exerts an influence on cognitive function, aligning with the existing body of literature. Nevertheless severe OH has not been reported to cause cognitive impairment. [7] Therefore, further research on OH is necessary. [12] When OH occurs for more than 3 min, it is called delayed OH and is considered as a marker of initial sympathetic failure. PD-OH in this study contained all types of OH (initial / classic / delayed), but no blood pressure change at 10 min was detected in this study and will be studied further in the future. OH may present with orthostatic symptoms and syncope or may be asymptomatic with. [3] Nigrostriatal dopaminergic denervation causes defective dopamine release causing motor disorders, whereas postganglionic sympathetic denervation causes reduced norepinephrine release and neurogenic OH while standing. When standing, perfusion pressure decreases, and cerebral autoregulatory mechanisms help to protect the brain from hypoperfusion. The precise mechanism by which OH operates remains undetermined. However, studies have shown that, associated changes in several distinct central regions, including the dorsal motor nucleus and the medial lateral cell column, have been identified. [30], [31] Neurogenic OH is due to insufficient noradrenaline release from sympathetic neurons due to degeneration of central and/or peripheral autonomic pathways and a subsequent failure to maintain sufficient peripheral vascular resistance for postural challenges. [14], [16], [32] Patients were classified into tremor – dominant, motor stiffness - dominant, PIGD types, and those with gait difficulties. The prevalence of PIGD - type PD was slightly higher, with 34 cases (52.3%). This study demonstrated that the classification of PD was not associated with OH. Among PD patients, those with OH tended to be older, have a longer disease duration, a later H&Y stage, and a larger daily total LEDD [14], which was consistent with the present study. Future studies in this area are expected to further refine our understanding. Sometimes, especially in the early stages of the disease, the clinical distinction between MSA and PD may be difficult. The integration of autonomic function tests with meticulous clinical assessment may facilitate the differentiation between PD and MSA.Statistical analysis revealed that LEDD medications could induce hypotension, and the LEDD levels in the OH - WD group were notably higher than those in other groups, suggesting that long - term use of LEDD drugs may exacerbate the onset of OH. It is well established that dopaminergic drugs (such as levodopa) significantly increase the risk of OH. [33], [34], [35] Clinicians must balance the improvement of motor function with the avoidance of hypotension. At the same time, dopaminergic medications themselves act as “cognitive modulators”. They can improve attention and executive function in PD patients. And nearly all classes of antihypertensive drugs (especially diuretics and alpha/beta blockers) may induce OH by reducing blood volume or dilating blood vessels. [36], [37] Therefore, controlling for the effects of medication on cognitive function and OH is crucial for the results. PD patients exhibited a reduction in CBFv during periods of rest, particularly in mean and diastolic measurements, in comparison to healthy individuals. [25] In this study, PD patients decreased in mCBFv and DBP at baseline compared with the healthy group, but the statistical difference was not reached. Statistically, the greatest disparity in SBP is observed during the initial minute, attributed to a transient disorder in blood pressure regulation; subsequent adaptation to the upright posture at the 3rd and 5th minutes allows for a progressive increase in blood pressure. Meanwhile, mCBFvR remains consistently below the normal level due to the loss of W spike, resulting in a further decrease in CBFv. Our research reveals an independent association between OH and cerebrovascular parameters measured by TCD. There is a complex two - tiered mechanistic model of the relationship between OH and cerebral blood flow regulation in patients with PD. The first tier posits that the broad association between OH and abnormal cerebral blood flow is mainly propelled by a shared upstream pathological process, namely disease progression. This accounts for why the effects of OH are concealed after adjusting for disease severity. More profound findings surface from the second layer: after controlling for disease burden, the independent adverse impact of OH on cerebral blood flow is partially counteracted by the immediate cardiovascular compensatory response it elicits. Only when we further account for these compensatory haemodynamic variables (such as blood pressure, heart rate, and the presence of the W spike) in our analysis can the inherent, chronic, and adverse net effect of OH itself be clearly identified. This implies that OH exerts a dual influence on the cerebrovascular system: 1. as an indicator of disease severity, emerging concurrently with other neurological complications; and 2. as a direct pathophysiological stressor, exerting a persistent negative effect on cerebrovascular health, the severity of which is masked to a certain degree by the body's immediate compensatory mechanisms. Moreover, the fact that this result was only observed during the 5 min mCBFvR indicates that the impact of OH on cerebral blood flow perfusion becomes evident as time passes. During the supine-and-standing test, both OH and the attenuation of the W spike were observed to diminish cognitive function. It is postulated that in the advanced stages of OH, the prevalence of diminished W spike regression escalates, thereby augmenting the risk of cognitive decline. Notably, cognitive reserve and compensatory mechanisms in the brain may mask cognitive differences during mild-to-moderate OH stages. Future studies requiring larger sample sizes and employing more sophisticated neuropsychological assessment tools are needed to determine the specific dose-response threshold at which OH impacts cognition. Horizontal cerebral blood flow was defined as 100%, and PD patients with OH or poor W spike correction had significantly lower mCBFvR in the 1st, 3rd, and 5th minutes, while in PD patients with OH, up to 87.5%, OCHO and 95.8%. The incidence of orthostatic intolerance OI symptoms such as dizziness was 62.5%, which was significantly higher than that in the PD-NOH group. Combined with the absence of OH and W spike callback, PD was divided into four groups, and the incidence of OCHO in the W spike disappeared group (with or without OH) was 100%, which was significantly higher than that in the W spike presence group, indicating that W spike was closely related to cerebral hypoperfusion. Among them, patients with OH exhibiting poor W spike correction showed a significant reduction in orthostatic cerebral perfusion; while the MoCA scores and incidence of CD in this group have also significantly increased. OH represents a manifestation of autonomic nervous system dysfunction, and a significant proportion of individuals afflicted with OH exhibit the absence of the W spike. There exists substantial evidence to suggest that this phenomenon is correlated with diminished cerebral perfusion and resultant cognitive impairment. Furthermore, when combined with the widely acknowledged cognitive disorders within the pathophysiological framework of the vascular mechanism theory, intermittent hypotension leads to intermittent low perfusion in brain tissue, resulting in local subcortical cerebral ischemia, which in turn induces white matter degeneration and secondary cognitive impairment. [38] Consequently, we have obtained evidence that OH and W spike abnormalities are associated with cognitive impairment. Given that loss of w regulation affects prolonged orthostatic cerebral perfusion, that changes in cerebral hemodynamics usually occur early in cognitive impairment and that prolonged cerebral hypoperfusion affects cognitive function, the overall cerebral hypoperfusion observed in diagnosed CD can test this theory. There is a large body of research data showing that changes in cerebrovascular hemodynamics are seen in CD and that a reduction in cerebral blood flow velocity is equally evident in the neurodegenerative and vascular aspects of dementia [39], [40], [41]. Via mediator analysis, the independent variable OH exerts a significant overall influence on the dependent variable cognitive function, and this direct influence endures even after controlling for mediating variables. However, the TCD parameter 5-min mCBFvR did not play a significant mediating role. It is possible that TCD is not, in fact, an effective mediating pathway between OH and cognitive decline. However, owing to the insufficient sample size, the statistical power was inadequate, which might have led to the failure to detect the actual mediating effect. Alternatively, there may be other mediating variables that were not incorporated into the analysis. Further research is necessary to examine the mediating effects. Increasing evidence suggests an association between OH and an increased risk of dementia in patients with PD. [7], [15] In PD and MSA patients, the timing of OH was a factor associated with cognitive dysfunction, and the severity of OH symptoms did not increase the risk of cognitive impairment in both conditions. Recent studies suggest that OH can lead to significant cognitive impairment, potentially resulting in cognitive deficits and dementia, even in cases where symptoms are asymptomatic or mild. Repeated episodes of OH affecting cerebral perfusion and inducing chronic hypoxia is the most likely pathogenic mechanism. Both ischemic and neurodegenerative changes secondary to chronic hypoxia have been demonstrated in animal models and human studies. [16], [42], [43], [44] According to Braak staging [45], mild cognitive impairment begins to emerge in the fourth stage of cortical pathology accumulation. Existing studies indicate that non-motor symptoms of OH primarily accumulate in the dorsal motor nucleus and medial-lateral cell columns. Integrating current hypotheses suggests OH precedes cognitive decline in PD. A meta-analysis [46] indicated that while theoretical frameworks suggest neurodegeneration may drive both simultaneously, current epidemiological data lacks consensus. Some studies demonstrate an association, whereas more recent investigations fail to confirm this link. [46], [47] We recommend that these findings be further validated in prospective cohort studies in the future. Notably, univariate regression analysis revealed a positive correlation between disease duration, age, daily total LEDD doses, OH, and the risk of CD in PD patients; specifically, longer disease duration, older age, higher LEDD doses, or the presence of OH were associated with an increased likelihood of CD. With the extension of the disease course, the daily total LEDD dose and the prevalence of OH increased accordingly. According to previous studies, years of education can affect cognitive function, and this study did not show the effect of years of education on cognition, considering this association to be potentially due to an insufficient number of cases. After the gradual inclusion of age, the effect of OH on CD was significantly weakened and eventually lost statistical significance. The possibility of severe multicollinearity was excluded through variance expansion factor analysis. These findings collectively indicate that age acts as a primary confounding factor: it is independently associated with both OH and cognitive impairment. When adjusted for in the multivariate model, age accounted for a substantial portion of the risk otherwise attributed to OH, thereby diminishing its independent effect. Nevertheless, the correlation between OH and cognitive impairment in PD is intricate and has garnered recent scholarly attention. Certain investigations have revealed a substantial influence, as evidenced by the observation that PD patients with dementia tend to be of an older age compared to those without OH. This is in line with studies conducted on elderly individuals with OH, indicating that factors such as advanced age and the progression of the disease may contribute to cognitive deterioration, rather than OH itself. [25] According to guidelines from the American Autonomic Society and the European Autonomic Society, supine hypertension (SH) is defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg measured after at least 5 min of supine rest in patients with neurogenic OH. [33] Supine hypertension is common in patients with neurogenic OH caused by autonomic failure, representing a fundamental pathophysiological process as these individuals lack normal blood - pressure buffering mechanisms to counteract hypertension. [48] Neurogenic OH carries a risk of falls and may be associated with cognitive impairment in the short term, while chronic SH may be linked to stroke and myocardial infarction in the long term. [49] Unfortunately, this study monitored blood pressure in supine positions lasting over 5 min and collected SH data from 8 cases (one - third of OH cases). The statistical impact of SH on supine cerebral blood flow velocity showed no significant effect (Supporting Information 4). This may be related to the small sample size, and future studies will expand the sample size for further refinement. This study found that among the seven cognitive domains of cognitive function, individuals with PD combined with OH exhibited worse performance in the visual space domain compared to those with PD alone.(Supporting information 3) Recent studies found that patients with early and middle term PD dementia mainly showed “subcortical dementia”, with a more prominent decline in executive ability, consistent with the results of this study, while patients with advanced PD dementia have the characteristics of both “subcortical dementia” and “cortical dementia”. [50], [51] Abnormal findings in attention, executive ability, spatial vision ability and memory. The differences in attention and memory were not calculated in this study. Conclusion The incidence of OH in PD patients is positively correlated with age, medical history, HY stage, and the daily total LEDD volume. This study indicated that most patients PD exhibit PIGD typing, whereas OH was not associated with specific PD typing. OH in PD patients affects the correction of the W spike and reduces cerebral blood perfusion during prolonged upright posture, potentially contributing to cognitive impairment. Among the seven cognitive domains of cognitive function, those patients with PD with OH have the greatest impairment of visual spatial executive ability. Clinically, PD patients should undergo routine monitoring of TCD and AST to promptly detect OH. If OH is identified alongside the disappearance of W waves, vigilance for cognitive impairment is warranted. Based on the findings of this study, we recommend establishing a tiered management strategy in clinical practice: Routine Screening: Conduct AST for all PD patients. This is the most cost – effective, non - invasive, and efficient screening method. Advanced Evaluation: For patients with positive routine screening results or a history of falls/syncope, we recommend HUTT to confirm the diagnosis and severity of OH. By performing timely intervention on possible risk factors, it is possible to prevent the occurrence of malignant events such as falls and enhance the quality of life of PD patients. For complex cases that require a deeper understanding of cerebral perfusion status and its relationship with cognition, or in research settings, we recommend using TCD combined with tilt testing to assess cerebral vascular regulatory capacity. Limitations There are still some limitations to this study. The selected sample size is relatively small, and the partial selection bias cannot be excluded. For example, the stratified analysis of OH severity had insufficient power in subgroup analyses due to sample size limitations. The exclusion criteria regarding atrophy of the core regions may result in some patients with OH associated with early-stage neurodegenerative disorders being excluded, thereby introducing selection bias. If the number of patients with poor temporal window is large, cerebral blood flow monitoring is excluded; if patients with advanced H&Y stage cannot stand quickly and independently and the assistance of family members, resulting in the difference in rapid standing time and a certain degree of selection bias. In addition, in order to reduce the physical burden of patients, this study did not mandate a prolonged cessation of anti-PD drugs and antihypertensive medications for patients, nor did it examine the impact of these drugs on blood pressure and dynamic brain self-regulatory mechanisms. Finally, this study did not extend the standing duration during the monitoring of cerebral blood flow velocity in the upright position, nor did it investigate the classification of typical/delayed OH subtypes. Furthermore, the study did not delve into the supine hypertension subtype. Despite adjusting for multiple confounding factors, we cannot rule out the possibility that PD simultaneously contributes to both OH and cognitive decline. Given the cross - sectional design of this study, it is not possible to directly establish a causal relationship between OH and cognitive impairment. Further longitudinal studies are required. Common Abbreviations Reference Table. English abbreviationFull English namePDParkinson's diseaseOHorthostatic hypotensionCDcognitive declinePIGDpostural instability and gait difficultyLEDDlevodopa equivalent daily doseMSAmultiple system atrophyASTactive standing testMAPmean arterial pressureSBPsystolic blood pressureDBPdiastolic blood pressureMDS-UPDRSMovement Disorder Society unified Parkinson's disease rating scaleH&YHoehn and YahrMoCAMontreal cognitive assessmentTCDTranscranial DopplarMCAmiddle cerebral arteryHChealth controlmCBFvmean cerebral blood flow velocity,baselinepCBFvpeak cerebral blood flow velocityPIPulsatility IndexPD-OHParkinson's disease with orthostatic hypotensionPD-NOHParkinson's disease with non-orthostatic hypotensionQASATQuantitative Autonomic Reflex and Small Fibers TestsOCHOorthostatic cerebral hypoperfusionMIN mCBFvRminimum mean cerebral blood flow velocity ratio,% of baseline1 min mCBFvRmean cerebral blood flow velocity ratio at the 1st minute of tilt,% of baseline3 min mCBFvRmean cerebral blood flow velocity ratio at the 3rd minute of tilt,% of baseline5 min mCBFvRmean cerebral blood flow velocity ratio at the 5th minute of tilt,% of baselineOH-Worthostatic hypotension with the W spikeOH-WDorthostatic hypotension with the W spike disappearanceWDthe W spike disappearancePD-CDParkinson's disease with cognitive declinePD-NCParkinson's disease with normal cognitionPDCD - NOHParkinson's disease with cognitive decline with non-orthostatic hypotensionPDCD-OHParkinson's disease with cognitive decline and orthostatic hypotensionPD-WParkinson's disease with the W spikePD-WDParkinson's disease with the W spike disappearance English abbreviationFull English namePDParkinson's diseaseOHorthostatic hypotensionCDcognitive declinePIGDpostural instability and gait difficultyLEDDlevodopa equivalent daily doseMSAmultiple system atrophyASTactive standing testMAPmean arterial pressureSBPsystolic blood pressureDBPdiastolic blood pressureMDS-UPDRSMovement Disorder Society unified Parkinson's disease rating scaleH&YHoehn and YahrMoCAMontreal cognitive assessmentTCDTranscranial DopplarMCAmiddle cerebral arteryHChealth controlmCBFvmean cerebral blood flow velocity,baselinepCBFvpeak cerebral blood flow velocityPIPulsatility IndexPD-OHParkinson's disease with orthostatic hypotensionPD-NOHParkinson's disease with non-orthostatic hypotensionQASATQuantitative Autonomic Reflex and Small Fibers TestsOCHOorthostatic cerebral hypoperfusionMIN mCBFvRminimum mean cerebral blood flow velocity ratio,% of baseline1 min mCBFvRmean cerebral blood flow velocity ratio at the 1st minute of tilt,% of baseline3 min mCBFvRmean cerebral blood flow velocity ratio at the 3rd minute of tilt,% of baseline5 min mCBFvRmean cerebral blood flow velocity ratio at the 5th minute of tilt,% of baselineOH-Worthostatic hypotension with the W spikeOH-WDorthostatic hypotension with the W spike disappearanceWDthe W spike disappearancePD-CDParkinson's disease with cognitive declinePD-NCParkinson's disease with normal cognitionPDCD - NOHParkinson's disease with cognitive decline with non-orthostatic hypotensionPDCD-OHParkinson's disease with cognitive decline and orthostatic hypotensionPD-WParkinson's disease with the W spikePD-WDParkinson's disease with the W spike disappearance CRediT authorship contribution statement Jinyu Wang: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Yaqin Yu: Supervision, Software, Resources, Project administration, Methodology, Data curation, Conceptualization. Kaili Zhang: Software, Methodology, Formal analysis. Ruipeng Wang: Investigation, Data curation. Junwei Zhang: Investigation, Data curation. Donghai Li: Funding acquisition. Weihong Yan: Writing – review & editing, Visualization, Supervision, Resources, Project administration, Methodology, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jinyu Wang reports a relationship with Shanxi Bethune Hospital that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.